Lode Swinnen, MD
Medical Oncology · Baltimore, MDNPI 1417988148
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $24,825 of the $29,396 with a category attached, or 84.4%. 9 manufacturers reported payments, led by ADC Therapeutics America, Inc. at 37.5% of the total. Reporting peaked in 2023 at $10,973 and has fallen 98.6% since, to $150 in 2024.
Across 57 payments — averaging $515.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ADC Therapeutics America, Inc.$11K
- Pharmacyclics LLC, An Abbvie Company$8K
- AbbVie$7K
- Beigene, Ltd.$2K
- Adaptive Biotechnologies Corporation$1K
- Beigene USA, Inc.$112
- plus $177 from 3 others
Across 90 payments — averaging $21,741 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$1.7M
- Genentech, Inc.$232K
- Seagen Inc.$222
What the payments were for
- Consulting fees$24,82584%
- Travel & lodging$3,31511%
- Food & beverage$1,2294%
- Education$270%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ADC Therapeutics America, Inc. | 10 | $11,013 |
| Pharmacyclics LLC, An Abbvie Company | 23 | $8,349 |
| AbbVie | 17 | $6,595 |
| Beigene, Ltd. | 1 | $1,950 |
| Adaptive Biotechnologies Corporation | 1 | $1,200 |
| Beigene USA, Inc. | 2 | $112 |
| Morphosys, US Inc. | 1 | $83 |
| Genentech USA, Inc. | 1 | $79 |
| F. Hoffmann-la Roche AG | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$29,396 in reported general payments places this provider in the 75th percentile of 180 medical oncology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Baltimore
- Mario EisenbergerBaltimore$2.9M
- David SidranskyBaltimore$520K
- Carole MillerBaltimore$331K
- Mark LevisBaltimore$323K
- Tanguy Lim-SeiwertBaltimore$301K
- Shruti ChaturvediBaltimore$265K
- Sandy KotiahBaltimore$247K
- Bruce SmithBaltimore$235K
- Evan LipsonBaltimore$228K
- Nilofer AzadBaltimore$143K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.